Eric Walker added Resistance to last resort drug arose in patient over 3 weeks to a number of topics

Eric Walker added Evaluating the Role of New Beta-Lactam Agents for Uncommon Pathogens to a number of topics

Eric Walker added a number of topics and a number of links to Extended spectrum beta-lactamases (ESBL), and added Extended spectrum beta-lactamases (ESBL) to Beta-lactamases

Eric Walker added Evaluating the Role of New Beta-Lactam Agents for Uncommon Pathogens to L2 β-lactamase, and added L2 β-lactamase to Cephalosporinases

Eric Walker added Keith S. Kaye, MD, MPH: RESTORE-IMI 2 and Treating Critically Ill Patients With Respiratory Infections and Keith Kaye, MD, MPH, on the Approval of Imipenem/Cilastatin + Relebactam to AmpC cephalosporinase, and added AmpC cephalosporinase to Cephalosporinases

Eric Walker added L2 β-lactamase and AmpC cephalosporinase and Evaluating the Role of New Beta-Lactam Agents for Uncommon Pathogens and Resistance to last resort drug arose in patient over 3 weeks to Cephalosporinases, and added Cephalosporinases to Extended spectrum beta-lactamases (ESBL) and Cephalosporins

Eric Walker added a number of topics and a number of links to Cephalosporins, and added Cephalosporins to Broad-spectrum antibiotics and Beta-lactam antibiotics